AstraZeneca inks deal with Leo Pharma for dermatology meds tralokinumab and brodalumab
Jul 1 2016, 08:25 ET | About: AstraZeneca Group plc (AZN) | By: Mamta Mayani,
AstraZeneca (NYSE:AZN) enters into an agreement with privately held Danish drug firm LEO Pharma for a global licence to tralokinumab and European rights to brodalumab.
Under the terms of the agreement, LEO Pharma will make an upfront payment to AstraZeneca of $115M for the exclusive, global rights to tralokinumab for skin diseases. It will also pay AstraZeneca up to $1B in commercially-related milestones and royalties on product sales.
AstraZeneca reacquired the European rights to brodalumab from Valeant Pharmaceuticals (NYSE:VRX), who will continue to lead development and commercialization in the U.S. and other markets not covered by Kyowa Hakko Kirin (Japan and certain other Asian countries). LEO Pharma acquired the European rights under similar terms as Valeant, including paying a low single-digit royalty to AstraZeneca.
Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.
Brodalumab is an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis and in development for psoriatic arthritis.
The tralokinumab deal should be completed in Q3. The brodalumab deal was effective at signing. Neither will impact AstraZeneca's financial guidance for this year.
===============
-Aardig om 2 redenen:
-Valeant stoot een stukje sales in Europa af
-LEOPharma kennen we nog als het bedrijf dat samen met GTCB, het "zusterbedrijf" van Pharming, een preparaat ontwikkelde met behulp van de transgene technologie maar plotsklaps de samenwerking opzegde.